Shanxi Shuangyan Health Industry (Group) Co., Ltd_Shanxi Shuangyan Health Industry (Group) Co., Ltd

Create an international first-class Synthetic biology enterprise

Full-Supply-Chain Customization Expert in Intelligent Pharmaceutical Manufacturing

Founded in 2004 and headquartered in Datong, Shanxi Province, our company is a modernized pharmaceutical group with an asset scale of 2.25 billion RMB.We have established a comprehensive industry chain ecosystem pharmaceutical intermediates, APIs and FPP, holds international authoritative certificates such as FDA/EMA, and our product and service network covers 32 countries and regions around the world.

【Core Competencies】

Intelligent Strength

540,000㎡ Intelligent Pharmaceutical Industrial Park

1,200+ Professional Team (14% R&D personnel)

Annual Production Capacity:

APIs & Intermediates: 10,000 tons

Oral Solid Dosage: 5 billion units

Sterile Powder Injections: 600 million vials

Technical Powerhouse

Bio-Fermentation Technology Platform (8 production lines compliant with international standards)

Continuous Flow Chemistry Synthesis R&D Center

Intelligent Formulation Engineering Platform (Comprehensive dosage forms: Tablets/Capsules/Granules/sustained-release dosage forms/Sterile Preparations)

Quality Testing Center Equipped with Cutting-Edge Instruments Compliant with EU/US Quality Systems

International Certification

Triple International Certifications: FDA cGMP Compliance | EDQM Certification | WHO-PQ Approved Workshop

【Global Services】

Services for Global Partners

Custom Intermediates & CDMO Solutions

ANDA/MAH Co-Submission Support

ICH-Compliant Stability Studies

Global Regulatory Documentation & Submissions

Base on China, Connected to the World

Enzyme preparations and intermediates

A comprehensive pharmaceutical enterprise characterized by biological enzyme preparations and relying on intermediates. Based on Synthetic biology, the company accelerates the research of Biotransformation technology and gene metabolism engineering technology, improves the construction, screening, transformation and industrial application system of industrial enzymes and gene engineering strains, and becomes the leader of Synthetic biology industry。

Enzymic preparations

Specializing in the production of Cephalosporin, penicillin series, amino acid derivatives, Antiviral drug intermediates, with leading biological enzyme technology and production capacity
Pharma intermediates

One of the three largest domestic manufacturers of D-p-hydroxy Phenylglycine methyl ester; GSK, Aurobindo and other international customer certified products. The first domestic enzymatic production line of D-p-hydroxy Phenylglycine

Raw materials and preparations

A modern high-tech enterprise that integrates drug research and development, production, and sales. The company has a complete industrial chain of pharmaceutical intermediates, raw materials, and formulation products。

The company focuses on the integration of raw materials and preparations; Focus on developing high-value, hemp essence series products; Accelerate the development of high-end formulations such as sustained and controlled release products。

API industry

The raw material industry involves various aspects of raw materials such as digestive system, respiratory system, psychotropic drugs, cardiovascular and cerebrovascular drugs, and anti infective drugs。
Pharmaceutical industry

Covering various solid preparations such as digestion, respiration, minerals, cardiovascular system, etc。

R&D and Innovation

Group Market Map

After nearly a decade of experience, Shuangyan's sales performance has grown rapidly year by year, and its current sales have exceeded 1 billion yuan。

Shuangyan Group has actively expanded its global sales network over the years, with products selling well in over 50 countries and regions such as Europe, the United States, the Middle East, Africa, and Southeast Asia. Actively participate in the joint construction of the "the Belt and Road", establish trade relations with many countries along the "the Belt and Road", and constantly expand cooperation channels。

2 billion+
sales volume
50+
Best selling in countries and regions

Enterprise Chronicles

2004

Shanxi Xinbaoyuan Pharmaceutical was established
Professional production of local anesthesia and antitussive raw materials
2013

Production of bismuth agent
Introducing the original research "bismuth agent series" raw materials and preparation products and putting them into production, becoming the first domestic enterprise to complete the industrial chain of bismuth preparation products。
2014

Absorb and merge Spark Pharmaceuticals
Introducing medication for children, respiratory system, and cardiovascular systems; Enrich existing product lines。
2015

Biological enzyme pharmaceutical intermediates
Commercialized production of biological enzyme series production line and pharmaceutical intermediate D p-hydroxy Phenylglycine series production line。
2016

digestive system
The introduction of raw materials and preparations of trimebutine maleate has expanded the distribution of digestive system drugs。
2022

Shanxi Shuangyan Health Industry Group Established
Shanxi Shuangyan Biotechnology: Operating Biological Enzyme Series
Production of products, D-p-hydroxy Phenylglycine series intermediates。

Shanxi Shuangyan Pharmaceutical: engaged in the production of pharmaceutical raw materials and oral solid preparations。

Shanghai Banglin: front-end research and development of Synthetic biology and high-end preparation development。
2023

New Shuangyan Biopharmaceutical Industrial Park
The first phase covers an area of over 500 acres, with a planned investment of 1.5 billion yuan and 17 new workshops to further expand production capacity。
2024

Shuangyan Biopharmaceutical Industrial Park
All facilities have reached full operational capacity and achieved optimized production efficiency.

Enzymic preparations

Pharma intermediates

API industry

Pharmaceutical industry

Optimize the business environment relentlessly; ignite innov

The spirit of the plenary session boosts confidence, enterin

Government-Enterprise Collaboration Builds a Lifeline Shuang